Emergo Therapeutics is developing Norketotifen, a treatment that modulates the immune system to reduce hypercytokinemia associated with long COVID and influenza-like illnesses. This approach targets the overactive release of inflammatory cytokines without causing immunosuppression, addressing a significant gap in effective treatments for these conditions.
Funding
$16.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Long COVID and influenza-like illnesses can trigger hypercytokinemia, or cytokine storm, where the immune system overreacts and releases excessive inflammatory cytokines. Current treatments often lack the ability to modulate the immune response effectively without causing broad immunosuppression, leaving a significant gap in addressing these conditions.
Solution
Emergo Therapeutics is developing Norketotifen, a therapeutic designed to modulate the immune system and restore equilibrium by curtailing the release of inflammation-inducing cytokines from mast cells and other immune components. Norketotifen aims to reduce hypercytokinemia associated with long COVID and influenza-like illnesses without causing immunosuppression. This targeted approach seeks to revolutionize treatment strategies and improve patient outcomes by addressing the overactive immune response while preserving its essential functions. The treatment is designed to speed up recovery from influenza and treat all COVID variants without side effects.
Target Audience
The primary target audience includes individuals suffering from long COVID and those affected by severe influenza-like illnesses, as well as healthcare providers seeking effective treatments for hypercytokinemia without inducing immunosuppression.
Features
- Modulates the immune system to restore equilibrium.
- Curtails the release of inflammation-inducing cytokines.
- Does not cause immunosuppression.
- Targets overactive mast cells.
- Designed to treat long COVID and influenza-like illnesses.
- Aims to speed up recovery from influenza.
- Intended to treat all COVID variants without side effects.